Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Novo Nordisk: STEP Young Phase 3 Trial With Semaglutide Shows Superior BMI Reduction At Week 68

(RTTNews) - Novo Nordisk (NVO, NOVOB.CO, NOV.DE) announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years old with obesity. The res

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

More from Monday 7 September →